文献速递前列腺癌

靶向前列腺健康检查:一种识别前列腺癌风险男性的新型筛查系统——来自逾18 000例PSA检测的真实世界证据

Targeted Prostate Health Checks, a Novel Screening System to Identify Men at Risk of Prostate Cancer: Real-world Evidence from More than 18 000 Prostate-specific Antigen Tests.
PubMed 文献 · Eur Urol Oncol · 2025-11-03

该研究评估了靶向前列腺健康检查(TPHC)项目在英格兰萨里和苏塞克斯地区通过初级保健记录邀请50-70岁(黑人或有家族史者45-70岁)男性进行PSA检测的效果。在18 317名有PSA结果的男性中,865例(4.7%)PSA升高,经mpMRI和LATP活检后诊断263例前列腺癌,其中221例为ISUP分级组2-5。结论认为该程序在不增加初级保健负担的情况下,通过现代诊断路径检测到有意义的前列腺癌。

要点

  • TPHC通过短信邀请和目标人群筛选,33%受邀者同意PSA检测。
  • PSA升高者中,84%确诊者为ISUP分级组2-5的前列腺癌。
  • 年龄相关PSA cutoffs下分级组2-5检出率为26%,≥3 ng/ml cutoff下为25%。

核心结论

  • TPHC项目在COVID-19大流行期间对未检测男性进行前列腺癌筛查,未增加初级保健负担。
  • 真实世界数据表明,通过MRI和LATP活检的现代路径可检测到有意义的前列腺癌。

研究设计与样本

  • 前瞻性真实世界研究,通过初级保健记录识别50-70岁男性(黑人或有家族史者45-70岁)。
  • 发送137 993条短信邀请66 911人,21 905人(33%)完成在线调查并同意PSA检测。
  • 18 317名男性获得PSA结果,865例(4.7%)PSA升高。

主要发现

  • 865例PSA升高者中,817例接受mpMRI,344例接受活检,263例诊断为前列腺癌。
  • 221例为ISUP分级组2-5前列腺癌,占诊断者的84%,占PSA检测者的1.2%。
  • 年龄相关PSA cutoffs下分级组2-5检出率为26%,≥3 ng/ml cutoff下为25%。
  • 调查后前列腺癌知识平均得分提高1.87分。

关键数值与推荐

  • 年龄相关PSA阈值:40-49岁>2.5 ng/ml,50-59岁>3.5 ng/ml,60-70岁>4.5 ng/ml。
  • 或PSA水平≥3 ng/ml触发转诊进行mpMRI,必要时行LATP活检。

临床怎么用

  • 可通过初级保健记录识别目标人群,短信邀请至在线平台获取信息并同意PSA检测。
  • PSA升高者按年龄相关阈值或≥3 ng/ml转诊mpMRI,必要时行LATP活检。
  • 检测结果应告知全科医生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The Targeted Prostate Health Check (TPHC) programme was set up to identify men with prostate cancer (PC) in the Surrey and Sussex region of England that was undetected during the COVID-19 era. We report outcomes for more than 18 000 prostate-specific antigen (PSA) checks using modern diagnostic techniques. METHODS: Men aged 50-70 yr, or 45-70 yr if Black or with a family history of PC, were identified via primary care (general practitioner [GP]) records. Text messages invited men to visit www.talkprostate.co.uk for information on PC and consent to PSA checks coordinated by Medefer, a virtual health care provider. Elevated age-related PSA (40-49 yr: >2.5 ng/ml; 50-59 yr: >3.5 ng/ml, 60-70 yr: >4.5 ng/ml) or a level ≥3 ng/ml triggered referral for multiparametric magnetic resonance imaging (mpMRI) and, if indicated, local anaesthetic transperineal (LATP) biopsy. GPs were informed of the results. KEY FINDINGS AND LIMITATIONS: From 137 993 text messages inviting 66 911 individuals, 21 905 (33%) completed online surveys and consented to a PSA check. Of 18 317 men with a PSA result, 865 had elevated PSA (4.7%). After 817 mpMRI examinations, 344 patients underwent biopsy, 263 were diagnosed with PC, and 221 had International Society of Urological Pathology grade group 2-5 PC (84% of those diagnosed, 1.2% of those with a PSA test). The detection rate for grade group 2-5 PC was 26% with the age-related PSA cutoffs, and 25% with the ≥3 ng/ml cutoff. The average PC knowledge score increased by 1.87 points after the survey. CONCLUSIONS AND CLINICAL IMPLICATIONS: The TPHC programme screened men for PC untested during the COVID-19 pandemic without burdening primary care. Men were targeted from at-risk groups and their awareness was raised. Real-world data demonstrate the detection of significant PC via a modern pathway using MRI and LATP biopsies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Langley S, Uribe-Lewis S, Uribe J, et al. Targeted Prostate Health Checks, a Novel Screening System to Identify Men at Risk of Prostate Cancer: Real-world Evidence from More than 18 000 Prostate-specific Antigen Tests. Eur Urol Oncol. 2025. PMID: 41188149. doi:10.1016/j.euo.2025.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。